How to transfer my Ozempic prescription to Florida

If you’re considering medications like Wegovy, Ozempic, or Mounjaro for weight management, you’ve likely wondered: Can I get these prescribed through telehealth? The short answer is yes—in most cases. But the details depend on where you live, who’s prescribing, and whether you meet clinical criteria.

This guide breaks down everything you need to know about accessing GLP-1 weight loss medications via telehealth in 2025, including federal rules, state-specific requirements, and what to expect from a legitimate online provider.

Understanding Federal Telehealth Rules for Weight Loss Medications

The Good News: No Federal In-Person Requirement

GLP-1 medications like Wegovy, Ozempic, and Mounjaro are not controlled substances. This is crucial because federal law—specifically the Ryan Haight Act—only requires an in-person exam before prescribing controlled drugs (like Adderall or opioids) via telemedicine.

Since semaglutide and tirzepatide don’t fall into that category, there’s no federal mandate for an in-person visit before your telehealth provider can write a prescription. The DEA’s current telehealth flexibilities (extended through December 31, 2025) primarily affect controlled substances, but they’ve also normalized telemedicine across healthcare—making virtual weight management more accessible than ever.

What Changed During COVID-19?

The pandemic accelerated telehealth adoption dramatically. Emergency waivers allowed providers to prescribe virtually without in-person exams, even for controlled medications. While those temporary rules are set to expire (with potential extensions expected), non-controlled medications like GLP-1s have remained consistently available via telehealth throughout and beyond the pandemic.

As of late 2025, telehealth prescribing of weight loss medications is well-established, with regulatory support continuing to grow.

Free consultations available with select providers only.

Get a free consultation

And find an affordable, caring specialist.

Find a provider

Free consultations available with select providers only.

State-Specific Requirements: Where the Rules Get Detailed

While federal law doesn’t require in-person visits for GLP-1 medications, individual states can—and do—impose their own standards. Here’s what varies by state:

In-Person Exam Requirements

Some states require an initial physical examination before prescribing weight loss medications:

States requiring initial in-person visits:

• Arkansas
• Delaware
• Georgia
• Mississippi
• New Jersey
• North Dakota
• South Carolina
• Texas

States allowing telehealth-only (no in-person required):

• California
• Connecticut
• Illinois
• New York
• Pennsylvania
• Washington

Additional State-Specific Rules

Florida requires:

• BMI of 30 or higher (or 27+ with comorbidities)
• Follow-up visits at least every 3 months during treatment

New Jersey and Virginia mandate:

• Comprehensive initial work-up including physical exam and lab tests
• Documentation of a personalized diet and exercise plan
• Informed consent specific to weight-loss therapy
• Virginia additionally requires follow-up within 30 days of starting treatment

Connecticut requires:

• Behavioral counseling component
• Documented diet and exercise plan as part of treatment

Who Can Prescribe: Understanding Provider Credentials

Medical Doctors and Doctors of Osteopathy (MDs/DOs)

All states allow licensed physicians to prescribe GLP-1 weight loss medications via telehealth, provided they’re licensed in the state where you’re located.

Nurse Practitioners (NPs) and Physician Assistants (PAs)

The prescribing authority for NPs and PAs varies significantly by state:

Full Independent Practice (NPs can prescribe without physician oversight):

• California
• Connecticut
• New York
• Utah
• Virginia (after 2 years of experience)
• Washington

Collaborative Practice (requires physician agreement/supervision):

• Arkansas
• Florida
• Georgia (recently expanded to allow Schedule II prescribing with delegation)
• Illinois
• Pennsylvania
• South Carolina
• Texas (very restricted—NPs need formal physician agreements)

Important note: Whether you see an MD, DO, NP, or PA for your telehealth consultation, the provider must be properly licensed in your state. Reputable telehealth platforms like Klarity Health ensure all providers meet state-specific credentialing requirements.

Are You Eligible? Clinical Criteria for GLP-1 Medications

Legitimate telehealth providers don’t hand out weight loss medications to anyone who asks. You’ll need to meet specific medical criteria:

Standard Eligibility Requirements

For FDA-approved obesity treatment (Wegovy), you typically need:

• BMI of 30 or higher (obesity), OR
• BMI of 27 or higher with at least one weight-related health condition (like type 2 diabetes, high blood pressure, or high cholesterol)
• Age 18 or older (some providers may have different age restrictions)
• Evidence of previous weight loss attempts through diet and exercise

Medical Screening

Expect your telehealth provider to screen for contraindications, including:

• Personal or family history of medullary thyroid carcinoma
• Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
• Pregnancy or planning to become pregnant
• History of pancreatitis
• Severe gastrointestinal disorders
• Active gallbladder disease

The Evaluation Process

A thorough telehealth consultation should include:

1. Detailed medical history review: Current medications, allergies, past medical conditions
2. Weight and vital signs: You’ll likely need to provide current height, weight, and blood pressure
3. Laboratory work: Some states require labs (blood glucose, kidney function, thyroid tests) before prescribing
4. Lifestyle assessment: Discussion of current diet, exercise habits, and previous weight loss attempts
5. Informed consent: Clear explanation of potential side effects, risks, and the importance of lifestyle modifications

What to Expect: The Telehealth Treatment Process

Initial Consultation

Your first virtual visit typically lasts 20-30 minutes and includes a live video conference with a licensed provider. During this appointment, you’ll:

• Complete a comprehensive health questionnaire
• Discuss your weight loss goals and medical history
• Review potential medication options
• Receive education about side effects and proper use
• Create a treatment plan that includes diet and exercise guidance

Many telehealth platforms, including Klarity Health, match you with providers who specialize in weight management and understand the nuances of GLP-1 therapy.

Prescription and Fulfillment

If approved, your provider will send an electronic prescription to your preferred pharmacy. Here’s what you need to know:

Starting doses and titration:

• Most patients start on the lowest dose to minimize side effects
• Dosage increases gradually over 16-20 weeks
• Initial prescriptions are often for 4 weeks to assess tolerance

Insurance vs. cash pay:

• Many telehealth services, including Klarity Health, work with both insurance and cash-pay options
• Transparent pricing helps you understand costs upfront
• Some medications may require prior authorization from insurance

Follow-Up Care

Regular monitoring is essential—and in some states, legally required:

Typical follow-up schedule:

• 1 month after starting (to assess tolerance and side effects)
• Every 2-3 months during active treatment
• Periodic lab work to monitor metabolic health

What providers monitor:

• Weight loss progress
• Side effects (nausea, GI issues, etc.)
• Medication adherence
• Diet and exercise compliance
• Need for dose adjustments

Red Flags: How to Identify Questionable Telehealth Services

The popularity of weight loss medications has unfortunately attracted some less-than-reputable online services. Protect yourself by watching for these warning signs:

Major Red Flags

Avoid services that:

• Guarantee prescriptions before evaluation: Legitimate providers assess first, prescribe only when appropriate
• Offer compounded or ‘generic’ versions: The FDA banned most compounded semaglutide in 2025 due to safety concerns—legitimate providers prescribe only FDA-approved medications
• Skip medical screening: A quick questionnaire without a live provider consultation is insufficient
• Don’t require follow-up: Ongoing monitoring is essential for safety and effectiveness
• Lack transparent licensing information: You should be able to verify your provider’s credentials and state licensure
• Use high-pressure sales tactics: Ethical providers educate, don’t coerce

What Legitimate Services Provide

Look for telehealth platforms that:

• Require live video consultations with licensed providers
• Clearly display provider credentials and state licenses
• Offer thorough medical evaluations and screening
• Schedule regular follow-up appointments
• Provide detailed informed consent about risks and alternatives
• Accept insurance and offer transparent cash pricing
• Have clear contact information and physical practice locations

Klarity Health meets all these standards, with licensed providers available across multiple states, transparent pricing, and a commitment to evidence-based weight management care.

Understanding the Medications: Wegovy, Ozempic, and Mounjaro

Wegovy (Semaglutide 2.4mg)

FDA approval: Chronic weight management (June 2021)

How it works: Weekly injection that mimics GLP-1, reducing appetite and slowing stomach emptying

Typical results: Average 15% body weight loss over 68 weeks when combined with lifestyle changes

Prescribing notes: FDA-approved specifically for obesity; compounded versions are no longer legally available as of May 2025

Ozempic (Semaglutide 0.5-1mg)

FDA approval: Type 2 diabetes management

Off-label use: Weight loss (using the same active ingredient as Wegovy at lower doses)

How it works: Same mechanism as Wegovy

Prescribing notes: When prescribed for weight loss, this is off-label use—reputable providers will document medical necessity and obtain informed consent

Mounjaro (Tirzepatide) / Zepbound

FDA approval: Mounjaro for type 2 diabetes; Zepbound (15mg tirzepatide) for obesity

How it works: Dual GLP-1/GIP receptor agonist—may produce more weight loss than semaglutide alone

Typical results: Average 20-22% body weight loss in clinical trials

Prescribing notes: Newer option with promising results; requires proper training on self-injection technique

Cost Considerations: Insurance vs. Cash Pay

Insurance Coverage

Coverage for GLP-1 weight loss medications varies significantly:

Medicare: Generally does not cover weight loss medications (though this may change with pending legislation)

Private insurance: Coverage depends on your specific plan

• Some require prior authorization
• May require documented BMI and comorbidities
• Often require evidence of previous weight loss attempts
• Step therapy may be required (trying other interventions first)

Cash Pay Options

Many patients pay out-of-pocket due to limited insurance coverage:

Typical monthly costs:

• Wegovy: $1,300-$1,500 without insurance
• Ozempic: $900-$1,000 (when used off-label)
• Mounjaro/Zepbound: $1,000-$1,200

Savings programs:

• Manufacturer savings cards (eligibility varies)
• Some telehealth platforms negotiate lower rates
• Generic versions are not yet available in the U.S.

Klarity Health accepts both insurance and offers transparent cash-pay pricing, helping you understand costs before starting treatment.

Looking Ahead: The Future of Telehealth Weight Management

Regulatory Trends

The trajectory is clear: telehealth access to weight management is expanding, not contracting.

Federal developments:

• DEA telehealth flexibilities extended through December 2025 (with further extensions expected)
• Congressional support for permanent telehealth provisions (TREATS Act and similar legislation)
• FDA continuing to monitor and regulate compounded medications

State movements:

• More states adopting full practice authority for nurse practitioners
• Streamlined interstate licensure compacts making multi-state practice easier
• Recognition that regular in-person visits can be barriers to effective obesity care

What This Means for Patients

You can expect:

• More provider availability: As more states embrace telehealth, finding qualified providers becomes easier
• Greater affordability: Increased competition and eventual generic options may reduce costs
• Better care coordination: Telehealth platforms integrating lab work, nutrition counseling, and follow-up in one place
• Continued safety focus: Regulators will maintain standards while expanding access

Frequently Asked Questions

Can I use telehealth for weight loss medication if I’m traveling?

You must be physically located in the state where your provider is licensed at the time of your telehealth appointment. If you travel frequently, discuss this with your provider—some telehealth platforms have providers licensed in multiple states.

Do I need to see the same provider for every follow-up?

It’s ideal for continuity of care, but many telehealth platforms allow you to see different providers within their network if needed. Your medical records and treatment plan follow you within the platform.

What if I experience side effects?

Contact your provider immediately if you experience severe side effects like persistent vomiting, severe abdominal pain, or signs of pancreatitis. Most platforms offer messaging or urgent consultations between scheduled appointments. Common side effects like mild nausea usually improve over time and can be managed with dose adjustments.

How long will I need to take these medications?

GLP-1 medications are typically prescribed long-term for obesity management. Clinical studies show that weight often returns when medications are discontinued. Your provider will work with you to determine the appropriate duration based on your individual response and goals.

What happens if my insurance denies coverage?

Your provider can help with the appeals process, providing medical documentation to support coverage. Many patients also explore manufacturer savings programs or cash-pay options through telehealth platforms that negotiate lower rates.

Take the Next Step With Klarity Health

If you’re ready to explore weight loss medication through telehealth, Klarity Health makes the process straightforward and transparent.

Why choose Klarity:

• Licensed providers in your state: We ensure full regulatory compliance
• Comprehensive evaluations: Thorough medical screening, not just quick questionnaires
• Flexible options: We accept both insurance and offer clear cash-pay pricing
• Ongoing support: Regular follow-ups to monitor your progress and adjust treatment
• Evidence-based care: Our providers follow current medical guidelines and FDA-approved protocols

Getting started is simple:

1. Complete an online intake form (10-15 minutes)
2. Schedule your video consultation with a licensed provider
3. Receive your personalized treatment plan and prescription (if appropriate)
4. Begin your weight loss journey with ongoing support

Klarity Health’s team of experienced providers understands that weight management is about more than just medication—it’s about sustainable lifestyle changes, addressing underlying health conditions, and providing support every step of the way.

Final Thoughts

Telehealth has transformed access to weight loss medications, making evidence-based obesity care available to millions who might otherwise face barriers. While regulations vary by state, the overall trend supports expanded access with appropriate medical oversight.

The key is choosing a reputable telehealth provider that prioritizes your safety, follows established medical guidelines, and provides comprehensive care—not just a prescription.

Remember: GLP-1 medications are powerful tools, but they work best when combined with nutrition counseling, regular exercise, and lifestyle modifications. The most successful patients view these medications as one component of a broader health transformation.

If you’re struggling with obesity or weight-related health conditions, telehealth may offer the convenient, affordable, and effective care option you’ve been looking for.

Research Sources

This article is based on current regulations and clinical guidelines verified as of December 17, 2025. Below are the key sources used:

1. DEA Announcement (November 2024) – ‘DEA and HHS Extend Telemedicine Flexibilities through 2025’ – Official federal regulatory update on telehealth prescribing rules (www.dea.gov)

2. Axios News (November 2024) – ‘COVID-era telehealth prescribing extended’ – Analysis of federal telehealth policy extensions and implications for patients (www.axios.com)

3. McDermott Will & Emery Legal Analysis (November 2024) – ‘DEA Extends Telemedicine Flexibilities for Controlled Substance Prescribing Through December 31, 2025’ – Expert legal interpretation of federal telehealth regulations (www.mwe.com)

4. Goodwin Procter Law Firm Alert (March 2024) – ‘The Changing Regulatory and Reimbursement Landscape for Weight-Loss Drugs’ – Comprehensive state-by-state regulatory analysis for Florida, New Jersey, Virginia, and Connecticut requirements (www.goodwinlaw.com)

5. Reuters Health News (May 2025) – ‘Hims to cut 4% of workforce amid ban on weight loss drug copies’ – Coverage of FDA enforcement on compounded semaglutide and market impact (www.reuters.com)

Additional state-specific regulations were verified through official state medical board websites, pharmacy board guidelines, and legislative databases. All information current as of December 2025.

Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider before starting any weight loss medication. Individual results may vary, and medications may not be appropriate for everyone. Klarity Health providers conduct thorough evaluations to determine if GLP-1 medications are right for you.

Source:

• https://www.axios.com/2024/11/18/covid-telehealth-prescribing-extended-adderall#:~:text=The%20Drug%20Enforcement%20Administration%20,year%20extension
• https://www.dea.gov/documents/2024/2024-11/2024-11-15/dea-and-hhs-extend-telemedicine-flexibilities-through-2025#:~:text=telemedicine%20flexibilities%20through%20December%2031%2C,HHS%20on%20November%2015%2C%202024
• https://www.mwe.com/insights/dea-signals-extension-of-telemedicine-flexibilities-for-controlled-substance-prescribing-for-2026/#:~:text=A%20new%20rule%20posted%20on,date%20of%20December%2031%2C%202025
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=,a%20final%20set%20of%20regulations
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=31%2C%202024.%20,In%20February%202023%2C%20the%20DEA
• https://www.mwe.com/insights/dea-extends-telemedicine-flexibilities-for-controlled-substance-prescribing-through-december-31-2025/#:~:text=to%20perform%20an%20in,rule%20regarding%20telemedicine%20prescribing%20of
• https://www.whitehouse.senate.gov/news/release/whitehouse-murkowski-warner-blackburn-urge-white-house-and-dea-to-extend-telehealth-flexibilities-for-substance-use-disorder-and-mental-health-treatment/#:~:text=Whitehouse%2C%20Murkowski%2C%20Warner%2C%20Blackburn%20Urge,substance%20use%20disorder%20treatment%20Washington
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,person%20examination
• https://www.nextech.com/blog/semaglutide-laws-by-state#:~:text=Who%20can%20prescribe%20semaglutide%3F%20,
• https://natlawreview.com/article/arkansas-it-again-telemedicine-regulation-arkansas-undergoes-additional-change#:~:text=Arkansas%20currently%20has%20one%20of,encounter%20to%20establish%20a%20valid